Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.

doi:10.1158/1078-0432.CCR-19-3467

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2020

Parikh Aparna R, Mojtahed Amikasra, Schneider Jaime L, Kanter Katie, Van Seventer Emily E, Fetter Isobel J, Thabet Ashraf, Fish Madeleine G, Teshome Bezaye, Fosbenner Kathryn, Nadres Brandon, Shahzade Heather A, Allen Jill N, Blaszkowsky Lawrence S, Ryan David P, Giantonio Bruce, Goyal Lipika, Nipp Ryan D, Roeland Eric, Weekes Colin D, Wo Jennifer Y, Zhu Andrew X, Dias-Santagata Dora, Iafrate A John, Lennerz Jochen K, Hong Theodore S, Siravegna Giulia, Horick Nora, Clark Jeffrey W, Corcoran Ryan B

Abstract excerpt

PURPOSE: ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in real-time. We explored whether the quantitative percent change in ctDNA early after therapy initiation can predict treatment response and progression-free survival (PFS) in patients with metastatic gastrointestinal cancer. EXPERIMENTAL DESIGN: A total of 138 patients with metastatic gastrointestinal cancers and tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Disease Progression

Share to Gastrointestinal Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Longitudinal Studies

Share to Neoplasm Metastasis

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 31941831
DOI: 10.1158/1078-0432.CCR-19-3467
PMCID: PMC7165022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.PMID 31941831Read ↗

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic ResponseSemantic proximity Read ↗

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.Semantic proximity Read ↗

Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors.Semantic proximity Read ↗

Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.Semantic proximity Read ↗

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancersSemantic proximity Read ↗

Development of circulating tumour DNA analysis for gastrointestinal cancersSemantic proximity Read ↗

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challengesSemantic proximity Read ↗

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity Read ↗

Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer.Semantic proximity Read ↗

Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment.Semantic proximity Read ↗

Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.